Table 2 Exposure characteristics in infected and vaccinated cohortsa

From: Neonatal and maternal outcomes following SARS-CoV-2 infection and COVID-19 vaccination: a population-based matched cohort study

 

Infected

Vaccinated

Number of pregnancies

4074

11379

Gestation at first exposure

Preconception

220 (5.4%)

1620 (14.2%)

2–19 weeks

1080 (26.5%)

3960 (34.8%)

≥20 weeks

2774 (68.1%)

5799 (51.0%)

Number of infections during exposure period

1

4030 (98.9%)

–

2

44 (1.1%)

–

Timing of infections (among neonates exposed to two infections in pregnancy)

<20weeks

3 (6.8%)

–

≥20 weeks

10 (22.7%)

–

Both

31 (70.5%)

–

Number of vaccinations during exposure period

1

–

3867 (34.0%)

2+

–

7512 (66.0%)

Vaccine type

Oxford-AstraZeneca ChAdOx1-s/nCoV-19

–

785 (6.9%)

Moderna mRNA-1273

–

1217 (10.7%)

Pfizer-BioNTech BNT162b2

–

8672 (76.2%)

Mixed Doses

–

705 (6.2%)

  1. aThe data presented related to Cohort 1: singleton pregnancies ending in a live or stillbirth at ≥20 + 0 gestation used for analyses of stillbirth and extended perinatal death outcomes. The exposed pregnancies included in Cohorts 2–10 differed slightly from those in Cohort 1. Characteristics of Cohorts 2–10 therefore differ from those shown above, although differences were minimal.